Results 101 to 110 of about 82,305 (279)

Confirming the presence of HTLV-1 infection and the absence of HTLV-2 in blood donors from Arequipa, Peru Confirmação da presença de infecção por HTLV-1 e ausência de infecção por HTLV-2 em doadores de sangue de Arequipa, Peru

open access: yesRevista do Instituto de Medicina Tropical de São Paulo, 2009
Epidemiological studies conducted in Peru disclosed HTLV-1 to be prevalent in different ethnic groups, and found HTLV-2 in some Amazonian Indians and in men who have sex with men.
Nadia Carmela Santos Quispe   +3 more
doaj   +1 more source

Functional investigation of the RHD gene promoter: Molecular changes are rarely responsible for variant D phenotype in Thai donors

open access: yesTransfusion, Volume 66, Issue 5, Page 957-963, May 2026.
Abstract Background While modern technology is increasingly available to identify efficiently the molecular alterations responsible for variant phenotype, a subset of samples still escapes those analyses. In addition to the promoter region, two intronic regions containing GATA1 binding sites within the RHD gene locus were recently shown to modulate the
Caroline Bénech   +2 more
wiley   +1 more source

HIGHLIGHTS ON DISTINCTIVE STRUCTURAL AND FUNCTIONAL PROPERTIES OF HTLV TAX PROTEINS.

open access: yesFrontiers in Microbiology, 2013
Human T-cell Leukemia Viruses (HTLVs) are complex human retroviruses of the Deltaretrovirus genus. Four types have been identified thus far, with HTLV-1 and HTLV-2 much more prevalent than HTLV-3 or -4 .
Maria Grazia Romanelli   +6 more
doaj   +1 more source

Pathogen‐reduced platelet concentrates in France: Impact on the risk of transfusion‐transmitted infections, 2017–2024

open access: yesVox Sanguinis, Volume 121, Issue 5, Page 581-586, May 2026.
Abstract Background and Objectives Pathogen reduction (PR) using amotosalen‐UVA was implemented for 100% of platelet concentrates (PCs) in France in November 2017. No bacterial testing was in place earlier. The impact of PR on the risk of transfusion‐transmitted infections (TTIs) from November 2017 to December 2022 (vs.
Syria Laperche   +11 more
wiley   +1 more source

Expression of interleukin 2 receptors on activated human B cells. [PDF]

open access: yes, 1984
Using anti-Tac, a monoclonal anti-interleukin 2 (IL-2) receptor antibody, we have explored the possibility that certain activated B cells display receptors for IL-2.
Bongiovanni, KF   +8 more
core  

High Prevalence and Risk Factors for Infection with Human T-Lymphotropic Viruses 1 and 2 in the Municipality of Ananindeua, Pará, Northern Brazil

open access: yesViruses
This descriptive, observational, cross-sectional study evaluated HTLV-1 and HTLV-2 infections in Ananindeua, northern Brazil. Individuals were screened for anti-HTLV-1/2 using ELISA (Murex HTLV-I + II, DiaSorin).
Dara da Costa Soares   +10 more
doaj   +1 more source

Hepatitis C viral load in HCV-monoinfected and HCV/HIV-1-, HCV/HTLV-1/-2-, and HCV/HIV/HTLV-1/-2-co-infected patients from São Paulo, Brazil

open access: yesBrazilian Journal of Infectious Diseases, 2018
Co-infections of hepatitis C virus (HCV) and either human immunodeficiency virus type 1 (HIV-1), human T-cell lymphotropic virus type 1 (HTLV-1) or type 2 (HTLV-2) have been described as having an impact on HCV viremia and subsequent disease progression.
Fabiana Aparecida Alves   +4 more
doaj   +1 more source

Cellular factors involved in HTLV-1 entry and pathogenicity

open access: yesFrontiers in Microbiology, 2012
Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T cell leukemia (ATL) and HTLV-1–associated myelopathy and tropical spastic paraparesis (HAM/TSP).
Hiroo eHoshino
doaj   +1 more source

A novel high-performance rapid screening test for the detection of total HTLV-I and HTLV-II antibodies in HTLV-I/II infected patients

open access: yesBMC Infectious Diseases
Rapid diagnosis of human T-cell lymphotropic virus (HTLV) type-I and -II infections are essential for timely and cost-effective disease interventions.
Lay Sin Teoh   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy